RAS Inhibition With Daraxonrasib Marks a Turning Point in Pancreatic Cancer Management

In this episode of Oncology Unplugged, host Chandler Park, MD, MSc, FACP, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by John L. Marshall, MD, the chief of hematology and oncology, a professor of medicine and oncology, and the director of the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.

Their discussion centered on the evolution of pancreatic adenocarcinoma management over the past several decades, culminating in the emergence of RAS-directed therapy. Drs Park and Marshall traced the treatment history from early regimens, such as fluorouracil/doxorubicin/mitomycin and single-agent fluorouracil, to the approval of gemcitabine based on clinical benefit, followed by years of gemcitabine-combination trials in which only capecitabine and nab-paclitaxel (Abraxane) produced positive results, and finally to FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin).

Dr Marshall explained RAS biology, emphasizing that since most pancreatic cancers harbor RAS mutations, severing this pathway can produce meaningful clinical benefit with a single agent, unlike in colorectal cancer. The experts reviewed data from the phase 3 RASolute 302 trial (NCT06625320) of the pan-RAS inhibitor daraxonrasib (Rasonque) presented at the 2026 ASCO Annual Meeting, in which second-line therapy yielded a median overall survival improvement vs chemotherapy. Dr Marshall tempered enthusiasm for these efficacy data by noting that response rates remained below 50% and that rash, affecting approximately 80% of patients, requires proactive prophylaxis, close follow-up, and dermatology collaboration. He cautioned against offering the agent to patients with poor performance status and discussed dose-optimization strategies.

Drs Park and Marshall also highlighted the importance of moving RAS inhibition into earlier lines of therapy, as only approximately 10% of patients are surgical candidates, as well as the need for comprehensive genomic testing, including germline BRCA1/2 testing to identify eligible candidates for treatment with olaparib (Lynparza). The conversation concluded with the potential role of artificial intelligence in predicting treatment benefit.